In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial)

Among patients who underwent coronary stenting and were randomized to eptifibatide (n=1,040) or placebo (n=1,024), use of eptifibatide reduced initial procedural costs by $151/patient ($4,423 vs $4,574, p=0.005) and costs related to ischemic complications by $61/patient ($283 vs $344, p=0.002).

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2002, Vol.89 (1), p.61-64
Main Authors: Cohen, David J., O’Shea, J.Conor, Pacchiana, Cindy M., Levine, Glenn, Sarembock, Ian, Slater, James, Conn, Eric, Smith, Jack, Tcheng, James E.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Coronary vessels
Drug therapy
Hospital costs
Medical sciences
Pharmacology. Drug treatments
Stents
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among patients who underwent coronary stenting and were randomized to eptifibatide (n=1,040) or placebo (n=1,024), use of eptifibatide reduced initial procedural costs by $151/patient ($4,423 vs $4,574, p=0.005) and costs related to ischemic complications by $61/patient ($283 vs $344, p=0.002).
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(01)02165-8